ACR 2021

Dear Doctor: JAKi risk factors and safety profile - is…

No need for methotrexate in ustekinumab treatment in…

ARIAA: prevention study or very early treatment of RA?

New treatment alternative in GCA: promising secukinumab…

Pulmonary involvement and possible therapy concepts in…

IL-17 pathway important for pain in PsA

Discordance between patients and physicians in RA

Long awaited - MACE data from ORAL surveillance

Statins reduce cardiovascular risk and​ mortality -…

Cardiovascular disease in RA

Tofacitinib is associated with a slightly increased…

Nausea & alopecia with MTX in RA

We need predictors of response for RA treatment

Cycling JAKi compared to switching to biologic DMARD in…

Abatacept may reduce subclinical inflammation in RA-at…

Las estatinas reducen el riesgo cardiovascular y la…

Tofacitinid se asocia con un ligero incremento del…

Skifte mellom JAK hemmere sammenliknet med skifte til…

Quels marqueurs de réponse aux traitements dans la…

Désaccords patient/Médecin : se comprendre pour plus…

Lange erwartet - MACE-Daten zur ORAL Surveillance

Abatacept reduce la inflamación subclínica en pacientes…

Association of C-reactive protein and non-steroidal…

Prediction of psoriatic arthritis in patients with…

Pain differs: Superior effect of IL-17-inhibition vs.…

Guselkumab: the better ustekinumab?!

No need for MTX in ustekinumab-treated patients

Joint effusions and enthesitis after physical exertion

PET/CT in diagnosis for PsA

Upadacitinib in PsA

Axial PsA MRI data

Tildrakizumab in PsA

Guselkumab in axial symptoms

Osteoporosis in PsA

Anemia is an issue in PsA - proper treatment possible!

Secukinumab vs TNF-α blockers in enthesitis

Guselkumab bei axialer Symptomatik

Studio di confronto tra i vari indici compositi per la…

Osteoporose bei PsA

Secukinumab vs TNF-α Blocker bei Enthesitis

Anämie bei PsA ist ein Thema - effektive Therapie…

Guselkumab: das bessere Ustekinumab?!

Tildrakizumab bei PsA

PET-CT zur Quantifizierung der Entzündung

Upadacitinib bei PsA

Gelenkergüsse und Enthesitis nach körperlicher…

Schmerz ist nicht gleich Schmerz: Unterschied von…

Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab

Associazione di livelli di PCR e uso di FANS con gli…

Datos de RM en APs axial

Self-monitoring of disease activity with a smartphone…

Axial PsA MRI data

Dose tapering of TNF inhibitors in axSpA

l’auto-monitoraggio di malattia è fattibile nella…

Optimización de iTNF en EspAax

Datos de RM en APs axial

Not yet a new standard: belimumab + rituximab

JAK-Inhibitor Baricitinib in Phase II erfolgreich

PET as a predictor of vascular damage in large-vessel…

A new therapeutic approach for giant cell arteritis?

Secukinumab in giant cell arteritis

Il ruolo della PET nel predire il danno vascolare nelle…

Baricitinib nell'arterite a cellule giganti recidivante

Secukinumab nell'arterite a cellule giganti

Immune responses to COVID-19 vaccines

Impact of COVID-19 on patients with rheumatic diseases

TNF blockers reduce the antibody response to RNA…

Should we use ultra-low-dose rituximab during the…

Analysis of COVID-19 infection among vaccinated…

Breakthrough infections after SARS-CoV2-vaccination -…

Booster with which one if there is no seroconversion?

Vaccination against Delta variant worse in patients…

Breakthrough infections after SARS-CoV2-vaccination -…

Immunresponser til COVID-19 vaksiner

Durchbruchsinfektionen nach SARS-CoV2-Impfung -…

TNF-Blocker reduzieren Antikörperantwort bei…

Womit boostern bei fehlender Serokonversion?

Schlechtere Neutralisation der Delta-Variante unter…

New exciting data - dietary supplements with vitamin D…

Skin findings in patients of color with rheumatic…

Pearls and myths in rheumatology

Therapeutic drug monitoring - a randomized controlled…

CBD - an alternative therapy for chronic pain

Neue spannende Daten - Nahrungsergänzung mit Vitamin D…